摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Bromophenyl)hex-2-yn-1-one | 1072835-11-0

中文名称
——
中文别名
——
英文名称
1-(4-Bromophenyl)hex-2-yn-1-one
英文别名
——
1-(4-Bromophenyl)hex-2-yn-1-one化学式
CAS
1072835-11-0
化学式
C12H11BrO
mdl
——
分子量
251.123
InChiKey
OQMMTLRTMJVIFX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    1-(4-Bromophenyl)hex-2-yn-1-one甲醇三乙基硅烷 、 sodium tetrahydroborate 、 eaton’s reagent 、 potassium carbonate三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 、 lithium hydroxide 作用下, 以 四氢呋喃二氯甲烷N,N-二甲基甲酰胺 为溶剂, 生成
    参考文献:
    名称:
    发现新型吲唑衍生物作为双重血管紧张素II拮抗剂和部分PPARγ激动剂
    摘要:
    描述了吲哚衍生物作为双重血管紧张素II 1型(AT 1)受体拮抗剂和部分过氧化物酶体增殖物激活的受体-γ(PPARγ)激动剂的鉴定。 从替米沙坦开始,我们先前曾描述过吲哚衍生物是非常有效的部分PPARγ激动剂,但AT 1受体拮抗剂的活性却下降了。 新的中央支架的设计,合成和评估使我们发现了吡唑并吡啶,然后吲唑衍生物提供了具有所需双重活性的新系列。 在这些新化合物中,有38种是 大鼠中具有良好口服生物利用度的有效AT 1受体拮抗剂(IC 50  = 0.006μM)和部分PPARγ激动剂(EC 50 = 0.25μM,最大40%)。 在高血压(SHR)和胰岛素抵抗(Zucker fa / fa rat)的两个临床前模型中证实了化合物38的双重药理作用。
    DOI:
    10.1016/j.bmcl.2014.01.004
  • 作为产物:
    描述:
    对溴苯甲醛 在 Jones reagent 、 乙基溴化镁 作用下, 以 四氢呋喃丙酮 为溶剂, 反应 16.0h, 生成 1-(4-Bromophenyl)hex-2-yn-1-one
    参考文献:
    名称:
    Synthesis and biological evaluation of 3-amino-2-pyrones as selective cyclooxygenase-1 (COX-1) inhibitors
    摘要:
    A group of 3-amino-2-pyrones were synthesized and their biological activities were evaluated for inhibiting cyclooxygenase (COX) activity. This study has led to the identification of COX-1-selective inhibitors. Among the tested compounds, the compound 5j exhibited the most potent COX-1 inhibitory activity (IC50 = 19.32 mu g/mL) and COX-1 selectivity index (SI = 41.98). (C) 2013 Qing-Fa Zhou. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
    DOI:
    10.1016/j.cclet.2013.01.005
点击查看最新优质反应信息

文献信息

  • PPh<sub>3</sub>-KOBu<sup>t</sup>–Mediated Cyclization Reaction of <font>β</font>-Ketoesters with Alkynyl Ketones: Synthesis of Functionalized 2-Pyrones
    作者:Bin Hu、Ling-Guo Meng、Xiao-Li Hao、Mao Liang、Song Xue
    DOI:10.1080/00397911.2010.517374
    日期:2011.11.1
    Abstract Cyclization of alkynyl ketones with β-ketoesters mediated by PPh3 and KOBut to synthesize 2-pyrone derivatives was systematically described. A variety of β-ketoesters reacted with alkynyl ketones to give functionalized 2-pyrones in moderate to good yields under mild conditions.
    摘要 系统地描述了由 PPh3 和 KOBut 介导的炔基酮与 β-酮酯环化合成 2-吡喃酮衍生物。各种 β-酮酯与炔基酮反应,在温和条件下以中等至良好的产率得到官能化的 2-吡喃酮。
  • Michael Addition-Lactonization Reaction of Electron-Deficient Alkynes with N-(Diphenylmethylene)glycinates: An Efficient Synthesis of 3-Amino-2-pyrone Derivatives
    作者:Tao Lu、Qing-Fa Zhou、Yong Zhu、Wei-Fang Tang
    DOI:10.1055/s-0029-1217098
    日期:2010.1
    approach is based on the Michael addition of N-(diphenylmethylene)glycinates to various alkynyl ketones, followed by lactonization using 10 mol% sodium hydroxide as catalyst. Aromatic and aliphatic alkynyl ketones were converted into the corresponding 3-amino-2-pyrone derivatives in moderate to high yields. When methyl propiolate was submitted to the reaction, α,β-dehydroamino acids were formed in good
    已经开发了温和而有效的合成3-氨基-2-吡喃酮衍生物的方法。该方法基于将N-(二苯基亚甲基)甘氨酸盐迈克尔加成到各种炔基酮中,然后使用10mol%氢氧化钠作为催化剂进行内酯化。将芳族和脂族炔基酮以中等至高产率转化为相应的3-氨基-2-吡喃酮衍生物。当丙酸甲酯进行反应时,以良好的产率形成α,β-脱氢氨基酸。 3-氨基-2-吡喃酮衍生物-炔基酮-迈克尔加成-内酯化-合成
  • Cycloaddition of Alkynyl Ketones with <i>N</i>-Tosylimines Catalyzed by Bu<sub>3</sub>P and DMAP: Synthesis of Highly Functionalized Pyrrolidines and Azetidines
    作者:Ling-Guo Meng、Peijie Cai、Qingxiang Guo、Song Xue
    DOI:10.1021/jo801687v
    日期:2008.11.7
    Cycloadditions of alkynyl ketones with N-tosylimines catalyzed by Lewis bases to synthesize azetidines and pyrrolidines were systematically described. In the reaction of alkynyl ketones with N-tosylimines catalyzed by Bu3P at room temperature in toluene, highly functionalized pyrrolidines were formed in good to excellent yields. When DMAP was used in place of Bu3P as catalyst to facilitate the cycloaddition, completely substituted azetidines were produced in moderate to good yields in CH2Cl2. Both cyclization reactions proceeded smoothly with complete stereoselectivity. The scope and limitations of these cycloadditon reactions were also investigated.
  • Synthesis and biological evaluation of 3-amino-2-pyrones as selective cyclooxygenase-1 (COX-1) inhibitors
    作者:Xue-Ping Chu、Qing-Fa Zhou、Shen Zhao、Fei-Fei Ge、Mian Fu、Jia-Peng Chen、Tao Lu
    DOI:10.1016/j.cclet.2013.01.005
    日期:2013.2
    A group of 3-amino-2-pyrones were synthesized and their biological activities were evaluated for inhibiting cyclooxygenase (COX) activity. This study has led to the identification of COX-1-selective inhibitors. Among the tested compounds, the compound 5j exhibited the most potent COX-1 inhibitory activity (IC50 = 19.32 mu g/mL) and COX-1 selectivity index (SI = 41.98). (C) 2013 Qing-Fa Zhou. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
  • Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists
    作者:Yann Lamotte、Nicolas Faucher、Julien Sançon、Olivier Pineau、Stéphane Sautet、Marie-Hélène Fouchet、Véronique Beneton、Jean-Jacques Tousaint、Yannick Saintillan、Nicolas Ancellin、Edwige Nicodeme、Didier Grillot、Paul Martres
    DOI:10.1016/j.bmcl.2014.01.004
    日期:2014.2
    angiotensin II type 1 (AT1) receptor antagonists and partial peroxisome proliferator-activated receptor-γ (PPARγ) agonists is described. Starting from Telmisartan, we previously described that indole derivatives were very potent partial PPARγ agonists with loss of AT1 receptor antagonist activity. Design, synthesis and evaluation of new central scaffolds led us to the discovery of pyrrazolopyridine then
    描述了吲哚衍生物作为双重血管紧张素II 1型(AT 1)受体拮抗剂和部分过氧化物酶体增殖物激活的受体-γ(PPARγ)激动剂的鉴定。 从替米沙坦开始,我们先前曾描述过吲哚衍生物是非常有效的部分PPARγ激动剂,但AT 1受体拮抗剂的活性却下降了。 新的中央支架的设计,合成和评估使我们发现了吡唑并吡啶,然后吲唑衍生物提供了具有所需双重活性的新系列。 在这些新化合物中,有38种是 大鼠中具有良好口服生物利用度的有效AT 1受体拮抗剂(IC 50  = 0.006μM)和部分PPARγ激动剂(EC 50 = 0.25μM,最大40%)。 在高血压(SHR)和胰岛素抵抗(Zucker fa / fa rat)的两个临床前模型中证实了化合物38的双重药理作用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐